Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -36.49% is in line with its 5-year average of -36.67%, near the low end of its 5-year range (-50.22%–20.14%).
As of the fiscal period ended Tuesday, June 30, 2026. 282.71% below its 12-month average of -9.54%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -36.49%.
RETURN ON INVESTED CAPITAL (ROIC)
-36.49%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-9.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-26.45%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-36.67%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-282.71%
CURRENT VS 3Y AVG
-37.97%
CURRENT VS 5Y AVG
+0.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-2.38%
vs the sector median at left
Keros Therapeutics, Inc.
Market Cap
$218.30M
Return on Invested Capital (ROIC)
-36.49%
TTM Avg
-9.54%
3Y Avg
-26.45%
5Y Avg
-36.67%
Market Cap
$216.91M
Return on Invested Capital (ROIC)
-43.74%
TTM Avg
-105.81%
3Y Avg
-81.36%
5Y Avg
-65.49%
Market Cap
$220.93M
Return on Invested Capital (ROIC)
-61.03%
TTM Avg
-35.41%
3Y Avg
-48.95%
5Y Avg
-41.87%
Market Cap
$215.07M
Return on Invested Capital (ROIC)
19.13%
TTM Avg
15.37%
3Y Avg
31.31%
5Y Avg
44.42%
Market Cap
$214.46M
Return on Invested Capital (ROIC)
-40.18%
TTM Avg
-34.28%
3Y Avg
-58.87%
5Y Avg
-58.87%
Market Cap
$214.24M
Return on Invested Capital (ROIC)
8.84%
TTM Avg
15.21%
3Y Avg
-9.34%
5Y Avg
-32.56%
Market Cap
$225.24M
Return on Invested Capital (ROIC)
-40.52%
TTM Avg
-35.57%
3Y Avg
-28.84%
5Y Avg
-24.57%
Market Cap
$210.98M
Return on Invested Capital (ROIC)
-70.80%
TTM Avg
-76.09%
3Y Avg
-51.87%
5Y Avg
-42.00%
Market Cap
$210.41M
Return on Invested Capital (ROIC)
-63.61%
TTM Avg
-17.34%
3Y Avg
-19.38%
5Y Avg
-26.83%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $218.30M | -36.49% | -9.54% | -26.45% | -36.67% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -43.74% | -105.81% | -81.36% | -65.49% |
| Profound Medical Corp. (PROF)vs › | $220.93M | -61.03% | -35.41% | -48.95% | -41.87% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 19.13% | 15.37% | 31.31% | 44.42% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -40.18% | -34.28% | -58.87% | -58.87% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 8.84% | 15.21% | -9.34% | -32.56% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | -40.52% | -35.57% | -28.84% | -24.57% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -70.80% | -76.09% | -51.87% | -42.00% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -63.61% | -17.34% | -19.38% | -26.83% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 26.14% | 3.79% | -12.27% | -17.37% |
ROIC
-36.5%
ROE
-31.7%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -36.49% |
| 2026-03-31 | -36.85% |
| 2025-12-31 | 20.14% |
| 2025-09-30 | 5.49% |
| 2025-06-30 | 0.03% |
| 2025-03-31 | -0.76% |
| 2024-12-31 | -35.83% |
| 2024-09-30 | -37.08% |
| 2024-06-30 | -43.49% |
| 2024-03-31 | -38.44% |
| 2023-12-31 | -49.17% |
| 2023-09-30 | -50.22% |
| 2023-06-30 | -41.19% |
| 2023-03-31 | -35.11% |
| 2022-12-31 | -39.55% |
| 2022-09-30 | -36.38% |
| 2022-06-30 | -37.84% |
| 2022-03-31 | -28.96% |
| 2021-12-31 | -23.16% |
| 2021-09-30 | -29.60% |
| 2021-06-30 | -23.97% |
| 2021-03-31 | -20.87% |
| 2020-12-31 | -17.79% |
| 2020-09-30 | -27.46% |
| 2020-06-30 | -18.62% |
| 2020-03-31 | -34.92% |
| 2019-12-31 | -163.29% |
